Data / Drug companies / Sun Pharmaceutical Industries, Inc.
Sun Pharmaceutical Industries, Inc.: 66 products in the FDA NDC directory, labeler code 63304
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Sun Pharmaceutical Industries, Inc. (labeler code 63304) lists 66 products in the FDA National Drug Code Directory, covering 24 finished drugs by generic name. By type: 64 prescription drugs, 2 over the counter drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on July 30, 2026.
The request: Watch Sun Pharmaceutical Industries, Inc. (FDA labeler code 63304): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 63304
- Products in commercial distribution
- 66
- Packages
- 156
- Finished drugs by generic name
- 24
- Prescription products
- 64
- Over the counter products
- 2
- Controlled substance products
- Schedule II 5, Schedule IV 4
- Flagged as original packager
- 44 of 44 products that carry the flag
- Started marketing in the last 12 months
- 4
- Products with a marketing end date set
- 1
- Earliest marketing start
- December 26, 2000
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 57 | 86.4% |
| New drug applications (NDA) | 7 | 10.6% |
| Authorized generics (NDA) | 2 | 3% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 64 | 97% |
| Over the counter drugs | 2 | 3% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Doxycycline | 7 | 63 |
| Lenalidomide | 6 | 19 |
| Risperidone | 5 | 43 |
| Morphine sulfate | 5 | 31 |
| Sunitinib malate | 4 | 9 |
| Potassium chloride | 4 | 84 |
| Metoprolol succinate | 4 | 46 |
| Dapagliflozin and metformin hydrochloride | 3 | 10 |
| Droxidopa | 3 | 15 |
| Lorazepam | 3 | 38 |
| Guaifenesin and dextromethorphan hbr | 2 | 26 |
| Ondansetron | 2 | 52 |
| Clindamycin hydrochloride | 2 | 34 |
| Mesalamine | 2 | 41 |
| Valacyclovir | 2 | 27 |
| Desvenlafaxine | 2 | 14 |
| Lubiprostone | 2 | 20 |
| Esomeprazole magnesium | 2 | 77 |
| Diltiazem hydrochloride | 1 | 55 |
| Cevimeline | 1 | 1 |
| Pentazocine and naloxone | 1 | 1 |
| Fosamprenavir calcium | 1 | 2 |
| Dextromethorphan hydrobromide and quinidine sulphate | 1 | 2 |
| Pazopanib | 1 | 6 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Capsule | 20 | 30.3% |
| Tablet, film coated | 9 | 13.6% |
| Capsule, extended release | 8 | 12.1% |
| Tablet, film coated, extended release | 8 | 12.1% |
| Tablet, extended release | 6 | 9.1% |
| Tablet, orally disintegrating | 5 | 7.6% |
| Tablet | 4 | 6.1% |
| Capsule, gelatin coated | 2 | 3% |
| Capsule, delayed release | 2 | 3% |
| Tablet, coated | 1 | 1.5% |
| Tablet, delayed release | 1 | 1.5% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Dextromethorphan Hydrobromide and Quinidine Sulphate | 63304-650 | Capsule | Generic drugs (ANDA) | July 30, 2026 |
| Dapagliflozin and Metformin Hydrochloride | 63304-028 | Tablet, film coated, extended release | Generic drugs (ANDA) | April 6, 2026 |
| Dapagliflozin and Metformin Hydrochloride | 63304-027 | Tablet, film coated, extended release | Generic drugs (ANDA) | April 6, 2026 |
| Dapagliflozin and Metformin Hydrochloride | 63304-026 | Tablet, film coated, extended release | Generic drugs (ANDA) | April 6, 2026 |
| Esomeprazole magnesium | 63304-735 | Capsule, delayed release | Generic drugs (ANDA) | September 18, 2025 |
| Esomeprazole magnesium | 63304-734 | Capsule, delayed release | Generic drugs (ANDA) | September 18, 2025 |
| Potassium Chloride | 63304-987 | Tablet, extended release | Generic drugs (ANDA) | November 14, 2023 |
| Pazopanib | 63304-116 | Tablet, film coated | Generic drugs (ANDA) | October 20, 2023 |
| Lorazepam | 63304-774 | Tablet | Generic drugs (ANDA) | June 25, 2023 |
| Lorazepam | 63304-773 | Tablet | Generic drugs (ANDA) | June 25, 2023 |
| Lorazepam | 63304-772 | Tablet | Generic drugs (ANDA) | June 25, 2023 |
| Lenalidomide | 63304-045 | Capsule | Generic drugs (ANDA) | March 12, 2023 |
| Lenalidomide | 63304-041 | Capsule | Generic drugs (ANDA) | March 12, 2023 |
| Lenalidomide | 63304-046 | Capsule | Generic drugs (ANDA) | March 4, 2023 |
| Lenalidomide | 63304-044 | Capsule | Generic drugs (ANDA) | March 4, 2023 |
| Lenalidomide | 63304-043 | Capsule | Generic drugs (ANDA) | March 4, 2023 |
| Lenalidomide | 63304-042 | Capsule | Generic drugs (ANDA) | March 4, 2023 |
| Lubiprostone | 63304-352 | Capsule, gelatin coated | Authorized generics (NDA) | January 1, 2023 |
| Lubiprostone | 63304-351 | Capsule, gelatin coated | Authorized generics (NDA) | January 1, 2023 |
| Mesalamine | 63304-089 | Capsule, extended release | Generic drugs (ANDA) | May 13, 2022 |
| Guaifenesin and Dextromethorphan HBr | 63304-110 | Tablet, extended release | Generic drugs (ANDA) | July 1, 2021 |
| Guaifenesin and Dextromethorphan HBr | 63304-106 | Tablet, extended release | Generic drugs (ANDA) | July 1, 2021 |
| Droxidopa | 63304-112 | Capsule | Generic drugs (ANDA) | February 18, 2021 |
| Droxidopa | 63304-104 | Capsule | Generic drugs (ANDA) | February 18, 2021 |
| Droxidopa | 63304-086 | Capsule | Generic drugs (ANDA) | February 18, 2021 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.